Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections

Kaminee Maduray1 · Raveen Parboosing1

Received: 20 July 2020 / Accepted: 28 September 2020 / Published online: 7 October 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract
Globally, viral diseases continue to pose a significant threat to public health. Recent outbreaks, such as influenza, coronavirus, Ebola, and dengue, have emphasized the urgent need for new antiviral therapeutics. Considerable efforts have focused on developing metal nanoparticles for the treatment of several pathogenic viruses. As a result of these efforts, metal nanoparticles are demonstrating promising antiviral activity against pathogenic surrogates and clinical isolates. This review summarizes the application of metal nanoparticles for the treatment of viral infections. It provides information on synthesis methods, size-related properties, nano-bio-interaction, and immunological effects of metal nanoparticles. This article also addresses critical criteria and considerations for developing clinically translatable nanosized metal particles to treat viral diseases.

Keywords Metal nanoparticle · Nanotherapeutics · Virus · Arbovirus · Treatment · Nanotechnology

Introduction
Nanotherapeutics has the potential to change the landscape of antiviral drug discovery and address issues related to resistance, emerging viruses, strain-specific targeting, and untreatable viral infections [1]. It uses nanoparticles (NPs) within the size range of 1–100 nm as a tool for drug delivery, diagnosis, and treatment of many infectious diseases [1–3]. Therapeutic NPs may be either inorganic (e.g., metal NPs) or organic (e.g., polymeric, liposomes, micelles, ferritin). Both types of NPs have been successful in pre-clinical studies and clinical settings for various medical conditions [4, 5]. Recently, progress in utilizing metal NPs as antiviral agents has advanced rapidly owing to the ability of metals having a multi-target “attack” on viruses, with minimal impact on the subsequent development of resistance [1, 6]. According to existing research, metal NPs have already proven to be active antiviral agents against human immunodeficiency virus (HIV), influenza virus, hepatitis virus, etc. [1, 6]. This review aims to discuss and highlight the synthesis, properties, reported antiviral activities, and immunological impact of metal NPs.

Synthesis of Metal Nanoparticles
There are wide arrays of physical, chemical, and biological methods to synthesize NPs [7]. In these methods, a three-component reaction of precursors, reducing agents, capping, or stabilizing agents is required [8]. Below is an overview of these methods.

Physical Method
The physical method for the synthesis of NPs include techniques such as ultraviolet (UV) radiation, microwave irradiation, sonochemical, thermal decomposition (thermolytic), photochemical, laser ablation, and radical induction [7, 9]. These techniques mainly utilize the top-down approach, prevent solvent contamination, and yield monodisperse NPs [9]. Synthesis proceeds from the evaporation of metal atoms to rapidly controlled condensation in which the metal atoms rearrange and aggregate to form small clusters of NPs [7]. Unfortunately, the abundant waste generated by physical methods for NP synthesis appears to be economically unfavorable [9].

Chemical Method
Chemical synthesis of metal NPs involves the bottom-up approach [7] with techniques such as the sol-gel method, microemulsion, hydrothermal synthesis, polyol synthesis,
and chemical vapor synthesis [9]. Nanoparticles of well-defined size, dimension, composition, and structure are produced through chemical methods [10]. The synthesis mechanism entails reducing metal ions by chemical reductants or decomposition of metal precursors with extra energy in the presence of a stabilizer [7]. Inorganic and organic solvents are frequently used as reducing agents [11]. Stabilizing agents (i.e., organic solvents, synthetic, or natural polymers) are also used to prevent agglomeration of metal NPs. Alternatively, surfactants containing functionalities (e.g., thiols, amines, acids, and alcohols) may also act as a stabilizer and protect particles from sedimentation, agglomeration, or losing their surface properties [12]. Despite the appealing advantages of chemically synthesized NPs, there may be essential disadvantages such as environmental pollution, NP unsuitability for specific biomedical applications, and the use of toxic and non-biodegradable chemicals [7, 13].

**Biological Method**

Biological synthesis of metal NPs depends on the bottom-up approach that employs unicellular and multicellular biological organisms (e.g., actinomycetes, bacteria, viruses, fungus, yeast, algae, and plants) [7, 14, 15]. Biogenic NPs are eco-friendly, quickly produced in large quantities, biocompatible, and of well-defined size and morphology [7, 16]. Several controlling factors influence the size, morphology, nucleation, and stability of biogenic NPs. These factors include pH, temperature, reactant concentration, synthesis time, etc. [17]. Microorganisms can produce metal NPs through either intracellular or extracellular routes. For example, metal ions transported into the microbial cell and trapped on the cell surface are enzymatically reduced to intracellularly and extracellularly synthesized NPs, respectively [14, 18]. Plant-based viruses such as cowpea chlorotic mottle virus (CCMV), cowpea mosaic virus (CPMV), brome mosaic virus (BMV), and tobacco mosaic virus (TMV) are used as biological templates to fabricate nanomaterial. The advantages of using plant viruses for nanomaterial synthesis include their small size, symmetric structure, ease of functionalization, monodispersity, and ability to self-assemble. Plant viruses are also non-infectious to humans and animals [19, 20]. Biological extracts from leaves, flowers, stems, seeds, and roots of various plant species are also considered safe and environmental friendly for metal NP synthesis. In plant extracts, the existing metabolites (i.e., sugars, terpenoids, alkaloids, phenolic acids, proteins) are primarily responsible for the bioreduction of metal ions for the formation of stable NPs [7, 17]. In order to avoid environmental toxicity, cytotoxicity, and carcinogenicity, biological methods are preferred [7, 21].

**Size-Related Properties and Nano-bio-interaction of Metal Nanoparticles**

Metal NPs exhibit properties and catalytic activity that is size dependant and influenced by their metal ion [22]. These properties include physical [23], chemical, biological [24], mechanical [25], optical, magnetic [26], etc. The smaller the size of the NP, the higher the melting point, thermal conductivity performance, and viscosity [23]. Surface area and surface free energy are increased in smaller size NPs compared with the larger size, which results in changes in interatomic spacing [23]. The optical band gap energy increases with the decrease in particle size. Therefore, metal NPs in colloidal solution appear in a variety of colors that are size and shape related due to the surface plasmon resonance [23]. The presence of a higher specific surface area, heterogeneous catalysis [27–29], and metal ions, such as transitional [30, 31], in smaller sized NPs, is considered advantageous for catalytic support.

Furthermore, the biological activities (i.e., antibacterial, antiviral, antifungal, and anticancer) of NPs significantly increase with decreasing particle size [1]. Besides, the reduced particle size offers the possibility of intravenous administration of poorly soluble NPs without any blockade of the blood capillaries [23]. The biological activities of NPs also depend on their metal ions, shape, potential, concentration, and method of preparation [1, 32]. In some instances, to stabilize and functionalize, metal NPs such as gold, silver, copper, palladium, and platinum ligands are used, due to their strong affinity towards the bare metal surfaces [33]. The binding affinity of ligands to cellular receptors increases proportionally with the size of the NPs because of the high protein content present on the surface of the NPs. The particle size is considered as the most crucial factor influencing cellular uptake and accumulation behaviors. Nanoparticles ranging from the size of 30–50 nm interact efficiently with cell membrane receptors and subsequently accumulate internally via receptor-mediated endocytosis. However, the optimal size for particle uptake is probably 50 nm since these sized particles offer a direct balance between the multivalent cross-linking of membrane receptors and the receptor-mediated endocytosis process [34]. In addition to size, the shape, composition, and surface charge of the NPs also influence cellular uptake and accumulation [32, 33]. Rod-shaped NPs tend to accumulate more than disc, spherical, cylinder, and cubed-shaped particles [32, 35]. Also, positively charged NPs achieve higher cellular uptake and accumulation internally by negatively charged cell membranes compared with neutral and negatively charged NPs [32].
**Antiviral Activity of Metal Nanoparticles**

The efficacy and antiviral activity of metal NPs depend on their size, shape, and metal ions. Notably, capped metal NPs present a significantly enhanced interaction with viruses and host cells than naked NPs [6]. The identified mechanisms of action for metal NPs can occur either inside or outside the host cells. These include the NP interacting with the gp120 proteins, competing with the virus for host cell-binding sites, interfering with the viral attachment, and blocking the virus-host binding or penetration. Other potential mechanisms of action involve inactivating the virus particles before cellular entry, interacting with the viral genome or binding to the viral particles. Furthermore, the intracellular compartment of an infected cell is abundant in virally encoded and host cellular factors required for viral replication and production of progeny virions. Therefore, the interaction of metal NPs with these replication factors is another antiviral mechanism of action [1, 6, 36].

Metal NPs, particularly silver and gold, have proven to exhibit antiviral activity against different viruses. The antiviral mechanism for gold NPs includes blocking of the gp120 attachment with CD4 to inhibit viral entry, whereas the antiviral mechanism of silver NPs involves inhibiting viral entry, attachment, or replication. For instance, silver NPs inhibit CD4-dependent virion binding, merging, and pathogenesis by interacting with the viral gp120 in the cell-free and cell-associated virus. In double-stranded RNA viruses, the silver NPs, after interaction with the viral genome, will inhibit viral replication [1, 6, 36]. Other metal NPs such as copper block the virus attachment, inhibit virus-cell binding, and viral entry into target cells. Copper NPs also destroy the viral genome and disrupt the capsid. Zinc NPs interfere with viral DNA polymerase activity resulting in viral replication inhibition. The inhibition of viral entry to the target cells depends on the ability of zinc NPs to bind to the virions. Iron NPs preferentially bind to the virus to inhibit it from binding to the cells. However, selenium NPs effectively protect the target cells from apoptosis caused by the infection of the virus [1, 6, 36].

**Immunological Effects of Metal Nanoparticles**

Metal NPs can interact with immune cells, such as macrophages, monocytes, dendritic cells, and lymphocytes, and potentially elicit modified immune responses [37]. However, the capacity of any metal NP to elicit an immune response depends on their physicochemical properties such as size, size distribution, surface area and reactivity, crystallinity, aggregation in a suitable medium, composition, surface coating, method of synthesis, and impurities [38, 39]. These immune responses include immunostimulation, immunosuppression, hypersensitivity, immunogenicity, and autoimmunity, comprising of both innate and adaptive immune responses [38, 40]. Therefore, the unexpected interaction with the immune system and modulation of the immune function by NPs can be beneficial or detrimental. In the future, metal NPs can be designed to be immunomodulatory to serve specific functions (e.g., vaccine adjuvants, anti-inflammatory, pro-inflammatory drugs) and improve the nanotreatment of infectious diseases. However, engineered immunomodulatory or conventional metal NPs that modify the immune system must reconcile with concerns about biocompatibility and immunotoxicity of nanomaterial [40–42].

Elevated cytokine levels, particularly pro-inflammatory, upon treatment with NPs have been associated with immunotoxicity and low therapeutic efficacy. At times, the elevation of both pro-inflammatory (e.g., IL-6 and TNF-α) and anti-inflammatory (e.g., IL-10) cytokine levels because of an unregulated innate immune response (i.e., cytokine storm) has made it more difficult to understand the underlying mechanisms of immunotoxicity [40, 43]. Therefore, metal NP purification is essential for removing iron contaminants and endotoxins that contribute to stimulating cytokine storms and exaggeration of inflammatory reactions. Nanoparticles may also generate large quantities of ROS that can trigger TNF receptors, resulting in the release of pro-inflammatory cytokines through the activation of the NF-κB transcription factor. In some cases, the inflammatory effect and release of cytokines can be inhibited by an enzyme, catalase, that protects against oxidative stress by catalyzing hydrogen peroxide decomposition into oxygen and water [43]. Nonetheless, a better understanding of the underlying interactions between metal NPs and the immune system is essential for the development of biocompatible, non-immunotoxic, and non-immunogenic nanomaterials for a variety of biomedical applications.

**Antiviral Potential of Metal Nanoparticles Against Different Viruses**

In recent years, there have been several reports on the antiviral activity of metal NPs, which are discussed below in detail and summarized in Table 1.

**Adenoviruses**

Human adenoviruses (HAdVs) are ubiquitous DNA viruses that possess a broad spectrum of pathogenicity. This virus is also associated with respiratory, gastrointestinal, urinary, and ocular illnesses in adults, infants, and immunocompromised individuals [44, 45]. Clinical treatment of HAdV infections focuses on alleviating the patient’s symptoms or the use of antiviral drugs, such as ribavirin and cidofovir for HAdV severe infections in immunocompromised individuals [44, 45]. Despite the encouraging treatment outcomes of cidofovir,
| Virus        | Type of metal nanoparticle | Average size of nanoparticle (nm) | Method of synthesis | Infected cell/animal model | Treatment strategy | Effective antiviral concentration | SI | References |
|--------------|---------------------------|-----------------------------------|---------------------|----------------------------|--------------------|------------------------------------|----|------------|
| Adenovirus   | Silver                    | 11.4                              | Chemical reduction  | HeLa cells (cervical cancer) | 3.125–400 μg/mL; 2 h | EC_{50}: 9.3 g/mL                  | -  | [47]       |
|             | Gold coated with silicon dioxide shell | 5-100                           | Sol-gel Grafting    | MDBK (Madin-Darby bovine kidney) cells | 200 μL (10-fold dilution); 3–7 days | IC_{50}: dilution 10^{-6} | -  | [48]       |
|             | Gold putted with silicon dioxide shell |                                |                     |                            |                    |                                   |    |            |
| Tungsten carbide |                              | 10–20 nm                         | Plasma atomization  | A549 cells (human lung carcinoma) cells | 100 mg/mL; 5–60 min | 3.5 log reduction: 100 mg/mL | -  | [49]       |
| Coronavirus  | Silver NP-graphene sheet  | 5–25 nm                          | Chemical            | Fcwf-4 cells (Felis catus whole fetus) | 0.1, 1, 10, 100 mg/mL; 96 h | Reduced viral particles from 3.8 × 10^2 to 2.5 × 10^5 PFU/mL; 46 μg/mL | -  | [57]       |
|             | Glutathione-capped silver sulfide | 5.3 nm                          | Chemical            | Vero cells (African green monkey; kidney epithelial) | 46 μg/mL; 12 h |                                   |    | [56]       |
|             | Gold nanorod-based HR1 peptide | 54 nm (length) 18 nm (diameter) | Chemical Solid phase | 293 T/MERS/EGFP cells and Huh-7 cells (human embryonic kidney and human liver) | 0–20 μM; 0–12 h | IC_{100}: 1.171 μM | -  | [55]       |
|             | Silver nanocluster with silica composite sputtered coating | Less than 200 nm | Radio frequency co-sputtering process with argon | Silver nanocluster/silica composite coating deposited on a facial FFP3 mask | Different silver concentrations; 72 h | 100% inhibition | -  | [58]       |
| Coxsackievirus | Silver                   | 57–146                           | Biological (plant extracts) | Vero cells | 125, 250, and 500 μg/mL; 48 h | IC_{50}: 344–375 μg/mL | 40 | [62]       |
|             | Silver                    | 8.91–27.89                       | Biological (plant extracts) | Vero cells | 5.28–520.6 μg/mL; 48 h | IC_{50}: 12.74 μg/mL | -  | [63]       |
| Enterovirus  | Selenium (functionalized with oseltamivir) | 10                              | Chemical            | U251 cells (human astrocytoma) | 9.8 μM of NPs (incl. 20 nM oseltamivir); 24–48 h |                          |    | [64]       |
|             | Selenium                  | 100                              | Chemical            | Vero cells | 15.625 μM; 48 h | IC_{50}: 500 μg/mL | 40 | [65]       |
| Chikungunya | Silver                    | 64–151                           | Biological (plant extract) | Vero cells | 1000–31.25 μg/mL; 5 days | IC_{50}: 62.5 μg/mL | -  | [75]       |
|             | Silver                    | 50–120                           | Biological (plant extracts) | Vero cells | 7.81–1000 μg/mL; 5 days | IC_{50}: 31.25, 125, and 250 μg/mL | -  | [76]       |
|             | Zinc oxide                | -                                | Precipitation method | MA104 cells (African green monkey fetal kidney) | 0.5–6.5 pg/mL; 4 days | 10-fold decrease in viral load: 2.5 pg/mL | -  | [77]       |
| Dengue      | Gold-small interfering RNA | 12.92–43.25 nm                   | Chemical            | Vero cells | 20–80 nM; 48–72 h | 80 nM | -  | [105]      |
|             | Silver                    | 30–70 nm                         | Biological (plant extract) | Vero cells | 10–100 μg/mL; 48 h | 30 μg/mL | -  | [108]      |
|             | Silver                    | 35–65 nm                         | Biological (alga)    | Vero cells | 6.25–50 μg/mL; 48 h | 6.25–50 μg/mL | -  | [107]      |
| Virus                        | Type of metal nanoparticle | Average size of nanoparticle (nm) | Method of synthesis | Infected cell/animal model | Treatment strategy | Effective antiviral concentration | SI | References |
|-----------------------------|----------------------------|----------------------------------|---------------------|---------------------------|------------------|-----------------------------------|----|------------|
| Herpes simplex              | Silver                     | 100 nm                           | Biological (seed extract) | Vero cells                | 10–40 μg/mL; 6, 24, 24 h | IC<sub>50</sub>: 50 μg/mL IC<sub>50</sub>: 12.5 μg/mL |    | [109]      |
|                             | Gold                       | -                                | Biological (seaweed extract) | Vero cells                | 2.5, 5, 10, and 25 μL; 72 h | HSV-1: 10 μL HSV-2: 25 μL |    | -          |
|                             | Silver                     | -                                | Biological (seaweed extract) | Vero cells                | 0.5, 1, 2.5, and 5 μL; 72 h | 2.5 μL | -          |
|                             | Silver-tannic acid         | 24 nm                            | Chemical reduction    | C57BL/6 mice              | 100 μL; 10 days       | HSV-1: 100 μL |    | [120]      |
|                             | Gold-3-mercaptoproxy sulfonate (MES) and heparin | 2.8 nm | Chemical reduction | Vero cells | 0.1–100 μg/mL; 24 h (HSV-1) and 48 h (HSV-2) | HSV-1: IC<sub>50</sub>:10.9 μg/mL HSV-2: EC<sub>50</sub>: 1.61 μg/mL CC<sub>50</sub>: > 300 μg/mL | HSV-1 > 27 HSV-2 > 52 | [118] |
|                             | Zinc oxide-rich in hydroxyl group (H-ZNPs) | 5–7 nm | H-ZNPs: co-precipitation | Vero cells | 0.1 and 0.24 mg/mL; 1, 2, 4, and 24 h | EC<sub>100</sub>: 0.01 mg/mL (C-ZNPs; H-ZNP) EC<sub>35</sub>: 0.01 mg/mL (OA-ZNPs) |    | -          |
|                             | Oligo acid-modified (OZ-ZNPs) | 40 nm | Commercially produced | Vero cells | 20–100 μg/mL; 48 h | HSV-1 EC<sub>50</sub>: 100 μg/mL | HSV-1 EC<sub>50</sub>: 32.3 μM HSV-2 EC<sub>50</sub>: 38.6 μM HSV-2 EC<sub>35</sub>: 25 μg/mL | HSV-1 > 30 HSV-2 > 25 | [113] |
|                             | Chitosan (C-ZNPs)          | 7.86 nm                          | Ultrasound induced rapid reduction of gallic acid (GA) | Vero cells | Different concentrations; 72 h | HSV-1 EC<sub>50</sub>: 100 μg/mL | HSV-1 EC<sub>50</sub>: 32.3 μM HSV-2 EC<sub>50</sub>: 38.6 μM HSV-2 EC<sub>35</sub>: 25 μg/mL | HSV-1 > 30 HSV-2 > 25 | [119] |
|                             | Copper oxide               | 40 nm                            | Commercially produced | Vero cells | 6.25–200 μg/mL; 48 h | 2.5 log reduction: 200 μg | - | [121] |
|                             | Gold                       | 30–40 nm                         | Commercially produced | Vero cells | 0.1–10 μg/mL; 48 h | EC<sub>50</sub>: 1–5 μg/mL | - | [122] |
|                             | Copper oxide               | 24–53 nm                         | Biological (fungi) | Vero cells | 0.5–8 g/mL; 72 h | 1, 2, and 4 μg/mL | - | [114] |
|                             | Zinc Oxide-PEGylated       | 20–50 nm                         | Commercially produced | Vero cells | 25–200 μg/mL; 48 h | 2.5 log reduction: 200 μg | - | [116] |
|                             | Silver-sodium              | -                                | Sonochemical          | HeLa cells                | 1–10 μg/mL; 72 h | HSV-1: 100 μg/mL | HSV-1: 100 μg/mL | - | [113] |
|                             | Silver-sodium              | -                                | Sonochemical          | HeLa cells                | 1–10 μg/mL; 72 h | HSV-1: 100 μg/mL | HSV-1: 100 μg/mL | - | [113] |
|                             | 2-mercaptoethane sulfonate (Ag-MES) | 5–7 nm | H-ZNPs: co-precipitation | Vero cells | 0.1 and 0.24 mg/mL; 1, 2, 4, and 24 h | EC<sub>100</sub>: 0.01 mg/mL (C-ZNPs; H-ZNP) EC<sub>35</sub>: 0.01 mg/mL (OA-ZNPs) |    | -          |
|                             | 2-mercaptoethane sulfonate (Ag-MES) | 40 nm | Commercially produced | Vero cells | 20–100 μg/mL; 48 h | HSV-1 EC<sub>50</sub>: 100 μg/mL | HSV-1 EC<sub>50</sub>: 32.3 μM HSV-2 EC<sub>50</sub>: 38.6 μM HSV-2 EC<sub>35</sub>: 25 μg/mL | HSV-1 > 30 HSV-2 > 25 | [113] |
|                             | Silver-sodium              | -                                | Sonochemical          | HeLa cells                | 1–10 μg/mL; 72 h | HSV-1: 100 μg/mL | HSV-1: 100 μg/mL | - | [113] |
|                             | Human immunodeficiency virus | 70–90 nm | Chemical reduction | HEK293T cells | 20, 40, 80, 120 μM; 72 h | IC<sub>50</sub>: 40 μM | 0.96 | [132] |
|                             | (HIV)                      | 46.8 nm                          | Micellar approach     | HTHU cells (Microglial)  | 5 and 8 mg/mL; 48 h | 8 mg/mL | - | [135] |
| Virus          | Type of metal nanoparticle                                                                 | Average size of nanoparticle (nm) | Method of synthesis | Infected cell/animal model | Treatment strategy | Effective antiviral concentration | SI | References |
|---------------|-------------------------------------------------------------------------------------------|----------------------------------|---------------------|---------------------------|--------------------|-----------------------------------|----|------------|
| Mesoporous curcumin encapsulated in iron-phenanthroline Gallium | -                                                                                     | Commerciaaly produced            | THP-1 macrophages     | 25–300 μM; 15 days       | 300 μM             | 0.025–0.075 μM                    | -  | [131]      |
| Glucan particle encapsulated gallium NP | < 30 nm                                                                                 | Low desorption                   | PBMC (primary peripheral blood mononuclear) | 26, 108, 150, and 355 μg Ga/mg glucan particle; 7 days | EC₅₀: 108–355 μg Ga/mg glucan particle | - |            |
| Silver        | 12–28 nm                                                                                 | Biological (leave extract)        | -                   | 0.25, 0.5, 0.75, and 1 μg/mL | IC₅₀: 0.4 μg/mL | -                                | -  | [178]      |
| Gold-synthetic (oligo) mannosides (Te-10 and Te-50) | 100 nm                                                                                 | Chemical                          | TZM-bl cells (HeLa cell derivative) | 2, 4, 5.5, 11 μM | Te-10: 11 and 5.5 μM Te-50: 4 and 2 μM | -  | [129]      |
| Gold          | 17 nm                                                                                   | Modified method of Turkevich     | HeLa-CD4-LTR-B-gal   | 0.01–0.8 mg/mL; 48 h     | IC₅₀: 1.12 mg/mL | -                                | -  | [128]      |
| Silver-curcumin | 45 nm                                                                                 | Biological                        | ACH-2 cells (acute lymphoblastic leukemia T cell) | 20–200 μL; 24–48 h | 100 μL                  | -                                | -  | [134]      |
| Hepatitis     | Silver                                    | 8.91–27.89 nm (plant extracts)     | Vero cells           | 5.28–520.6 μg/mL; 48 h  | IC₅₀: 520.6 μg/mL | IC₅₀: 36.36 μg/mL                    | -  | [63]       |
| Silver        | Cuprous oxide                             | 45.4 nm                          | Solution phase       | 2 μg/mL; 7 days          | > 0.2 μg/mL            | IC₅₀: 0.4 μg/mL                      | -  | [114]      |
| Influenza     | Selenium                                  | 200 nm                           | Chemical reduction and dialysis | 15.6 μg/mL; 48 h | 15.6 μM                  | -                                | -  | [144]      |
| Selenium      | Selenium-ribavirin                        | < 100 nm                         | 0.001–1 nM with 0.03–5% FluPep ligand; 48 h | Gold-FluPep | IC₅₀: 0.03% and 0.073 nM | Silver-FluPep | IC₅₀: 0.03% and 0.14 nM | IC₅₀: 125 μg/mL | [146] |
| Gold-FluPep   | Silver-FluPep                             | 10 nm                            | NPs-commercially produced conjugate-mixed matrix ligands | MDCK cells | 0.001–1 nM with 0.03–5% FluPep ligand; 48 h | Gold-FluPep | IC₅₀: 0.03% and 0.073 nM | Silver-FluPep | IC₅₀: 125 μg/mL | [146] |
| Silver        | 25–55 nm                                  | Biological (bark extract)        | Vero cells           | 31.25–500 μg/mL; 48 h   | IC₅₀: 12.5 μg/mL | IC₅₀: 12.5 μg/mL                    | -  | [147]      |
| Silver        | 10 nm                                     | MDCK cells (Madin-Darby canine kidney) | 6.25–200 μg/mL; 48–96 h | IC₅₀: 12.5 μg/mL | IC₅₀: 12.5 μg/mL | IC₅₀: 12.5 μg/mL | [148] |
| Silver        | 9.5 nm                                    | Oxidation-reduction method       | MDCK cells           | 12.5, 25, and 50 μg/mL; 48 h | IC₅₀: 12.5 μg/mL | IC₅₀: 12.5 μg/mL | [149] |
| Silver        | 3–2 nm                                    | Chemical reduction and dialysis  | MDCK cells           | 2.5 μg/mL; 24 h          | IC₅₀: 12.5 μg/mL | IC₅₀: 12.5 μg/mL | [145] |
| Silver        | Silver-oseltamivir                       | Ultra-sonication-assisted method (plant extract) | MDCK cells | 0.005–0.25 M; 24 h | 0.25 M             | IC₅₀: 1.1 pg  | [150] |
| Iron oxide    | 5–15 nm                                   | Chemical reduction and magnetic separation | MA104 cells (embryonic rhesus monkey kidney) | 0.5–6.5 pg; 4 days | IC₅₀: 1.1 pg  | -                                | [143] |
| Norovirus     | Gold-core                                 | 2–5 nm                           | MA104 cells (embryonic rhesus monkey kidney) | 0.0083–1.66 μM | IC₅₀: 0.083 μM | -                                | [154] |
| Virus                        | Type of metal nanoparticle | Average size of nanoparticle (nm) | Method of synthesis | Infected cell/animal model               | Treatment strategy                  | Effective antiviral concentration | SI | References |
|-----------------------------|---------------------------|-----------------------------------|---------------------|------------------------------------------|-------------------------------------|-----------------------------------|----|------------|
| Norovirus GI.1 (Norwalk)    | Copper sulfide            | 10, 75, 110 nm                    | Seeded growth method and core coating with CuS nanoshell       | CRFK cells (Crandell-Rees feline kidney) | 25, 50, and 100 μg/mL; 15 and 30 min; and 1, 2, and 4 h | 50 and 100 μg/mL (10 nm)          | -  | [156]      |
| Silver                      | Silver NP films           | 1.1 μm                            | Chemical reduction, coating, electrospinning technique        | RAW 264.7 cells (mouse leukemic macrophage) | 2.1 and 21 mg/L; 24 h | 0.86 log reduction | -  | [158]      |
| Anatase titanium dioxide    | Silver                    | 0.5–45 nm                         | Sol-gel                                                        | RAW 264.7 cells                                                                                  | 2 and 20 μg/mL; 24 and 48 h      | IC_50: 20 μg/mL                  | -  | [155]      |
| Tungsten carbide            | Silver NPs on magnetic hybrid colloid (MHC) | 10–20 nm | Plasma atomization | RAW 264.7 cells | 100 mg/mL; 5–60 min | 3.5 log reduction: 100 μg/mL | -  | [49]       |
| Poliovirus                  | Silver                    | 7.1 nm                            | Electrochemical                                              | RD cells (Human rhabdomyosarcoma)                                                               | 3.13–50 ppm; 30 and 60 min       | 3.13 ppm                         | -  | [162]      |
| Tungsten carbide            | Silver NPs coated with polyvinylpyrrolidone | 10 nm | Commercially produced | A549 cells, HEP-2 cells (laryngeal carcinoma) | 10, 25, and 50 μg/mL; 24 h | Decreased viral replication by 79% (A549) and 78% (HEP-2): 50 μg/mL | -  | [168]      |
| Respiratory syncytial virus infection (RSV) | Silver NPs-curcumin | 13.69 nm | Biological (curcumin) | HEP-2 cells | 0.008–0.24 nM; 24–72 h | 0.008–0.12 nM | -  | [167]      |
| Rift Valley fever virus     | Silver                    | 35 nm                             | Commercially produced                                         | Vero cells                                                                                      | 4.8–12 μg/mL; 24–72 h            | Reduced 98% of infectivity: 12 μg/mL | -  | [174]      |
| Rubeola virus               | Gold                      | 6 nm                              | Biological (garlic extract)                                   | Vero cells                                                                                      | 0.03–10 μg/mL; 72 h              | EC_50: 8.829 μg/mL 16.05         |    | [177]      |
therapeutic use is limited due to its low bioavailability and nephrotoxic effects [44, 46].

Silver, gold, and tungsten carbide NPs have been evaluated as potential therapeutics for the treatment of human adenovirus infections. Chen et al. [47] reported that silver NPs exhibited dose-dependent inhibitory activity on adenovirus in vitro. The half-maximal effective concentration (EC50) of the studied silver NPs against virally infected cells after 2 h of incubation was 9.3 μg/mL, and this concentration was not toxic to uninfected cells [47]. Lysenko et al. [48] synthesized two types of gold NPs as antiviral agents against adenovirus. Gold NPs coated with silicon dioxide shells and gold-silicon dioxide carrier NPs reduces the associated toxicity effects of gold ions. Both types of NPs showed to be effective against adenovirus with 96% and 100% inhibition. Pfaff et al. [49] showed that tungsten carbide NPs could reduce the infectivity of adenovirus type 5 by 50% in 15 min. These NPs also displayed significant antiviral activity against other types of viruses such as modified vaccina virus Ankara (MVA), poliovirus, and norovirus. In this regard, these NPs might be utilized as an effective nanotechnology-based disinfectant [49].

**Coronavirus**

Coronavirus (CoV) is an enveloped positive-sense RNA zoonotic virus [50]. In humans, it consists of a wide range of viruses contributing to the common cold and severe respiratory diseases such as the Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and novel coronavirus [51]. Epidemics of coronavirus emerge unexpectedly and spread quickly, causing an unusually high death toll, threatening human health and daily activities. These include the SARS-CoV and MERS-CoV epidemic in 2003 and 2012, respectively [51]. To date, the coronavirus disease 2019, (COVID-19) pandemic, is accelerating in infection and mortality rates worldwide [51]. The causative agent is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with no specific treatment or vaccine found to be successful in treating infected individuals [51].

Nanotechnology has received considerable attention from scientific communities as a vaccine [52], treatment, diagnostic, and protective source to combat coronavirus [51, 53, 54]. A recent study by Huang et al. [55] validated a new gold nanorod-based H1 peptide inhibitor (PIH-gold NRs) for MERS. At a concentration of 1.171 μM, PIH-gold NRs exhibited a 10-fold higher inhibitory activity than treatment with the peptide inhibitor only. Besides, at the same concentration, PIH-gold NRs completely inhibited cell fusion. This study further concluded that their newly developed PIH-gold NRs are biocompatible, biostable, and a highly effective anti-MERS agent [55]. Du et al. [56] validated that glutathione-capped silver sulfide nanoclusters, 5.3 nm in size, are active against porcine epidemic diarrhea virus (PEDV), a coronavirus model. Treatment with a concentration of 46 μg/mL for 12 h reduced plaque formation unit (PFU) from 3.8 × 10^5 to 2.5 × 10^2 per mL. This study also proposed that treatment with the studied nanoclusters inhibited PEDV infection by activating the production of IFN-stimulating genes (ISGs) and pro-inflammatory cytokines. These nanoclusters also prevented viral replication and budding [56]. Therefore, these results have paved the way for further research on other metal NPs (i.e., copper, zinc) to combat coronaviruses infections, such as COVID-19.

Researchers have also investigated the application of silver NPs to decrease the transmission of viruses in personal protection equipment. Graphene-silver nanocomposites, at a concentration of 0.1 mg/mL, inhibited 24.8% of infection by 4.7 × 10^4 TCID50 (tissue culture infective dose required to kill 50% of the infected host) per mL of feline coronavirus [57]. Silver nanocluster silica composite sputtered coating applied to the facial FFP3 mask, ultimately reduced the titer of SARS-CoV-2 to zero [58]. Therefore, applications of NPs for personal protection equipment to decrease the transmission of coronaviruses and other viruses require further consideration.

**Coxsackievirus and Other Enteroviruses**

Coxsackievirus is an enterovirus, associated with the hand, foot, and mouth disease (HFMD), acute febrile illness in children, acute localized exanthema, myocarditis, hepatitis, and pancreatitis. Intrauterine infection and feral demise are also coxsackievirus-related infections during pregnancy [59, 60]. There are no specific antiviral therapies available. Therefore, the preferred treatment regimen includes medication to reduce symptoms and manage pain [59, 61]. Salem et al. [62] found that silver NPs with aqueous leave and fruit extracts from *Ricinus communis* inhibited Coxsackievirus at half-maximal inhibitory concentrations (IC50) of 344 to 375 μg/mL, possibly by acting as a fusion inhibitor. Haggag et al. [63] found that silver NPs with extracts from *Lampranthus coccineus* showed significant antiviral activity against Coxackievirus at an IC50 of 12.74 μg/mL. Furthermore, molecular docking findings predicted that an existing interaction between the biosynthesized NPs and Coxackievirus 3c protease was responsible for the antiviral activity [63].

Selenium NPs were found to be active against enterovirus. Also, selenium NPs conjugated with oseltamivir inhibited enterovirus activity by reducing the production of ROS in human astrocytoma cells [64]. Li et al. [65] reported that selenium NPs inhibited the Jun amino-terminal kinase (JNK) signaling pathway, p38 kinase, and ROS production, resulting in reducing the viral protein synthesis and viral yield [66] and controlling ROS [67], which promoted antiviral activity against enterovirus.
**Chikungunya Virus**

Chikungunya is a febrile disease caused by positive-sense single-stranded RNA alphavirus in the Togaviridae family. The virus is transmitted primarily by the mosquito belonging to the *Aedes* genus [68, 69]. The common symptoms include muscle pain, headache, nausea, fatigue, and rash. The virus can cause acute, subacute, or chronic disease. Complications such as eye, heart, neurological, and gastrointestinal are commonly seen in infants, adults with comorbidities, and elderly patients [70–72]. Occasionally, co-infections with other mosquito-borne viral infections such as dengue and Zika present an additional challenge during differential diagnosis and treatment [73]. There are no specific antivirals or vaccines available for chikungunya, except for symptomatic treatment [70]. Alternatively, control of the mosquito vector becomes the primary target for the effective management of chikungunya [74].

Metal NPs have also been reported to have potential antiviral and larvicidal activity against vector-borne diseases such as chikungunya. For example, Kaushik et al. [75] investigated silver NPs capped with plant extracts (*Carica papaya*), as an antiviral agent for chikungunya infection using Vero cells. The reported maximum non-toxic dose (MNTD) and ½MNTD of silver NPs were 125 μg/mL and 62.5 μg/mL, respectively. A concentration of 62.5 μg/mL of NPs induced 52% inhibition against chikungunya virus [75]. Similarly, the anti-chikungunya activity of silver NPs capped with extracts from *Andrographis paniculata* was reported, with a concentration of 31.25 μg/mL (MNTD) and 15.63 μg/mL (½MNTD) exhibiting 75–100% and 25–49% inhibition of cytopathogenic effects (CPE) respectively [76]. Treatment with low concentrations of zinc oxide (2.5 pg/mL) displayed anti-chikungunya activity by decreasing levels of viral RNA transcripts within 24 h of infection as revealed by RT-PCR [77]. Another study reported that copper oxide NPs synthesized using leaf extracts from *Tridax procumbens* displayed larvicidal activity against the chikungunya vector at a lethal dose (LD₅₀) of 4.209 mg/L [78]. Silver NPs capped with plants extracts from *Ambrosia arborescens*, paddy straw, *Rhzya stricta*, *Daemia extensa*, *Solanum mammosum L.*, *pilaquinga*, and *Hymenodictyon orixense* demonstrated larvicidal activity against the chikungunya vector at a LD₅₀ of 0.28 ppm [79], 13.625 ppm [80], 30.66 μg/mL [81], 3.842 ppm [82], 0.06 ppm [83], and 17.10–20.08 mg/mL [84] respectively.

**Dengue Virus**

Dengue is a mosquito-borne endemic infectious disease of tropical and subtropical countries, rapidly becoming a global burden [85]. The dengue virus causes symptoms of varying degrees, ranging from mild asymptomatic dengue fever to severe dengue hemorrhagic fever and dengue shock syndrome, which may be fatal. To date, there are no effective antiviral drugs and vaccine candidates for dengue. Therefore, clinical management focuses on supportive treatment [85–87]. Studies have investigated the larvicidal activity of copper [78, 88], selenium [89], gold [90–92], and silver [93–102] NPs, and demonstrated their potential for inactivating the significant mosquito vectors (genus *Aedes*) of dengue [103, 104]. Paul et al. [105] analyzed the antiviral activity of gold NPs conjugated with small interfering RNA against the dengue virus. These NPs were able to enter the infected Vero cells and significantly reduce dengue virus serotype 2 (DENV-2) replication and infectious virion release under both pre- and post-infection conditions [105]. Quach et al. [106] reported on a novel subunit vaccine with a hybrid containing gold NPs and domain III of the viral envelope protein (EDIII) for dengue virus. In this study, anti-EDIII antibodies were induced into mice immunized with the hybrid gold NPs in a size and concentration-dependent manner [106]. Also, biosynthesized silver NPs using algae (*Centroceras clavulatum*), plant (*Bruguiera cylindrica*), and seed (*Moringa oleifera*) extracts showed anti-dengue activity at concentrations of 12.5–50, 30, and 20 μg/mL, respectively [107–109].

**Herpes Simplex Virus**

Infection with herpes simplex virus, known as herpes, can be due to either herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2). Both types are highly prevalent within the human population [110]. HSV-1 is mainly transmitted orally (oral herpes), whereas HSV-2 through oral-genital contact (genital herpes) [111]. Herpes virus infections are recurrent, lifelong, and incurable. Current antiviral therapies (i.e., pharmacological, topical, systemic, or laser therapy) are known to prevent or shorten outbreaks and reduce the risk of transmission [112]. However, individuals with immunosuppression (due to human immunodeficiency virus (HIV) malignancies or transplantation) may develop HSV-1 and HSV-2 variants that are resistant to the current antiviral therapies [110].

Various nanomaterials, e.g., copper [113, 114], zinc [115, 116], gold [117–119], and silver [117, 120–122], have proven to be effective against herpes. Silver NPs tend to block herpesvirus entry into the host cell by competing for binding to cellular heparin sulfate via the sulfonate end group [123, 124], whereas zinc NPs inhibit viral DNA polymerase activity [116]. Copper NPs generate ROS to inactivate the HSV by oxidation of viral proteins or degradation of the viral genome [113]. Mercapto-ethyl sulfonate gold NPs (with or without surfactant) inhibited HSV-1 and HSV-2 in cell culture [117–119].
Incurable infectious diseases such as HIV are among the leading causes of death worldwide [125, 126]. There are currently more than 30 approved antiretroviral drugs for the treatment of HIV infection, which includes 13 single-tablet drug combinations of two or more antiretroviral drugs. Antiretroviral therapies (ART) can suppress HIV replication to undetectable levels, provided that patients adhere to treatment regimens [127]. However, globally, HIV remains a challenge despite significant progress in decreasing its incidence and mortality rate [126].

Various metal NPs such as iron, silver, gallium, and gold have shown to be active against HIV, resulting in decreased viral growth and replication [1]. Silver NPs bind to gp120 protein to inhibit CD4-dependent virion binding, fusion, and infectivity. Gallium NPs interact with the CD4 membrane, thereby inhibiting HIV infection in macrophages. Gold NPs inhibit virus entry and are virus-neutralizing agents [1]. Vijayakumar and Ganesan (2012) [128] reported that stabilized gold NPs were effective against the M-tropic, T-tropic, dual tropic, and resistant HIV isolates with a 50% inhibition concentration of 1.12 ± 0.05 μg/mL. Marradi et al. [129] synthesized gold NPs coated with synthetic oligomannosides (Te-50 and Te-10), present in gp120, to stimulate 2G12-mediated neutralization of HIV infection in TZM-bl reporter cells. The NP formulations at concentrations of 2 μM (Te-50) and 5.5 μM (Te-10) neutralized 50% of the HIV-1-infected cells [129]. Glucan conjugated with gallium NPs inhibited HIV in macrophages (> 80% inhibition with formulations containing 108–355 μg gallium/mg glucan particles) [130]. Another study has revealed that gallium NPs suppress the co-infection of HIV and tuberculosis [131]. Silver NPs (12–28 nm) with leaf extracts from mangrove Rhizophora lamarkkii also inhibited HIV-1 reverse transcriptase activity with the IC₅₀ value of 0.4 μg/mL [178]. Individually, silver NPs conjugated with either anionic linear globular dendrimer [132] or sodium 2-mercaptoethane sulfonate (Ag-MES) [124] inhibited HIV replication efficiently.

Curcumin has been known to have many therapeutic benefits that now includes antiviral activity [133–135]. Curcumin-stabilized silver NPs with a diameter of 45 nm, demonstrated non-toxic antiretroviral and immunomodulatory effects on ACH-2 cells latently infected with HIV-1 [134]. Another study determined that multifunctional mesoporous curcumin encapsulated in ironphenanthroline nanoclusters, with a particle size of 46.8 nm, significantly decreased the expression of HIV-p24, TNF-α factors, IL-8, and nitric oxide by 41% 61.2%, 41%, and 50.2%, respectively [135].

Globally, viral hepatitis has been confirmed as one of the leading causes of death, liver diseases, and disability. These liver diseases include cirrhosis, hepatocellular cancer, decompensated disease, and extrahepatic manifestations [136, 137]. Currently, hepatitis C is curable if detected early with the aid of direct-acting antiviral therapies. Hepatitis B is often manageable through oral nucleos(t)ide therapies with high-resistance barriers. Significant advances in the management of hepatitis D infection are occurring [136]. However, a cure for viral hepatitis remains elusive, in the setting of viral genetic persistence within the hepatocyte nucleus, even with suppressive antiviral therapy [136]. Therefore, a possible cure and future therapeutic options must consider the targeting of multiple viral replication pathways in order to eliminate viral hepatitis as a public health threat [136].

Silver NPs have shown renewed promise in their ability to inhibit hepatitis replication. In a study by Lu et al. [138], different size silver NPs (10, 50, and 80 nm) were evaluated as an antiviral agent against hepatitis B. In this study, the silver NPs, 10 nm in size, produced 38% and 80% viral inhibition with a concentration of 5 μM and 50 μM respectively, while the silver NPs of 50 nm were slightly more potent with 53% and 92% inhibition at a concentration of 5 μM and 50 μM, respectively [138]. Haggag et al. [63] have recently analyzed biosynthesized silver NPs with extracts from Lampranthus coccineus and Malephora lutea against hepatitis A. This study reported that these NPs exhibit antiviral activity against hepatitis A and protect the host cell from viral infectivity [63]. Hang et al. [114] also indicated that copper NPs blocked hepatitis infection at the entry and attachment stages. Therefore, these findings suggest that silver and copper NPs may have novel roles in treating chronic hepatitis patients.

Influenza

Influenza, commonly known as the flu, consists of three types of viruses (A, B, and C) that belong to the Orthomyxoviridae family. These are enveloped and negative-strand RNA viruses [139]. Influenza occurs globally as local outbreaks or seasonal epidemics [140]. In the past 100 years, four influenza pandemics have occurred: H1N1 Spanish influenza in 1918, H2N2 Asian influenza in 1957, H3N2 Hong Kong influenza in 1968, and H1N1 swine influenza in 2009. In 1977, the H1N1 virus re-emerged but did not cause a pandemic [140]. However, since 1918, a novel influenza virus emerged from each pandemic, either directly from an avian host (1918), by reassortment between an avian virus and a circulating human strain (1957 and 1968), or through influenza virus reassortment in pigs (2009) and spread to the human population, causing considerable morbidity and mortality [140–142].
Annual vaccination remains the critical mode of prevention against seasonal influenza; however, the vaccines are effective only if the antigenic matching of the vaccine strains corresponds with the circulating virus strains [142]. The antiviral drugs currently available against influenza viruses are amantadine, rimantadine, zanamivir, oseltamivir, peramivir, and baloxavir marboxil. Antiviral resistance, influenza A virus infections, and control of future influenza pandemics are still an ongoing global concern [142].

Several studies have demonstrated the efficacy of metal NPs as potential antiviral agents against the influenza virus [143]. Iron oxide NPs showed in vitro inhibition (50%) against the H1N1 influenza A virus strain using a low concentration of 1.1 pg [143]. Lin et al. [144] analyzed the antiviral effects of selenium NPs and their conjugate with a broad-spectrum antiviral drug, ribavirin (RBV). Influenza infected Madin-Darby canine kidney (MDCK) cells exposed to no treatment, RBV only, selenium NPs, and selenium NPs with RBV achieved a cell viability of 48.4%, 68.5%, 65.2%, and 80.6%, respectively [144]. In a study by Li et al. [145], silver NPs were used to co-deliver oseltamivir to inhibit the H1N1 influenza virus activity through ROS-mediated signaling pathways. Infected MDCK cells exposed to no treatment, oseltamivir, silver NPs, and oseltamivir delivered by silver NPs achieved a cell viability of 39%, 59%, 65%, and 90%, respectively. These results indicate that the antiviral activity of currently prescribed antiviral drugs is effectively strengthened when conjugated with metal NPs. Each of these studies also revealed that the antiviral drugs conjugated with NPs used blocking of the H1N1 from infecting MDCK cells, preventing caspase-3 activity and inhibiting viral accumulation of ROS as antiviral mechanisms of action [144, 145].

“FluPep” is an established peptide inhibitor of influenza type A virus; however, silver and gold peptide (FluPep) NPs were synthesized and tested for enhanced antiviral activity [146]. Silver and gold NPs functionalized with FluPep ligand (0.03%) showed inhibition (50%) against the influenza A virus strain at concentrations of 0.14 nM and 0.073 nM, respectively. Most importantly, the study demonstrated that conjugation of FluPep to silver and gold NPs enhanced its antiviral potency compared with the free peptides and are capable of targeting both influenza and bacterial co-infections [146]. Although these results suggest that functionalized NPs are useful antiviral agents against influenza, researchers have also found that non-functionalized metal NPs (i.e., silver) can be effective as well [147–150].

Silver NPs synthesized with Panax ginseng root extract using the sonication method exhibited antiviral activity against the influenza A virus (strain A/PR/8) [150]. Low anti-influenza activity was identified at NP concentrations of 0.005, 0.01, and 0.15 M, with inhibitory rates of 5.31%, 4.18%, and 5.97%, respectively. However, the anti-influenza effects improved by 7.10% and 15.12%, with concentrations of 0.02 and 0.25 M, respectively [150]. Silver NPs with extracts from cinnamon (bark) demonstrated antiviral activity against the highly pathogenic avian influenza virus subtype H7N3. The NP concentration that inhibited 50% of infectivity was 125 μg/mL. Additional findings revealed that active constituents in the cinnamon bark extract interacted with the virus to interfere with viral replication and inhibit viral entry into the host cell [147].

Xiang et al. [148] confirmed that silver NPs at 50 μg/mL exerted maximum anti-H1N1 influenza A virus activity. Additional findings revealed that the silver ions from the NPs inhibited viral growth by DNA interference, suppression of respiratory enzymes, and electron transport components [148]. Xiang et al. [149] also reported that silver NPs at a concentration of 50 μg/mL demonstrated significant antiviral activity against the H3N2 influenza virus (A/Human/Hubei/3/2005 strain). These results indicate that functionalized and green synthesized silver NPs could be promising anti-influenza therapeutics.

**Norovirus**

Noroviruses are positive-strand RNA viruses and highly contagious. Globally, it is an established etiological agent in acute gastroenteritis outbreaks affecting all age groups. The infection causes a sudden onset of vomiting, diarrhea, abdominal pain, and cramps after contact with contaminated food or infected individuals [151]. Norovirus can be life-threatening to children, especially undernourished children from developing countries [152], infants, older adults, and immunocompromised individuals [151]. There are no clinically approved antivirals and vaccines for norovirus infections [153] since the challenge is that the virus presents with a vast genetic diversity, with over thirty different genotypes infecting humans [151].

Metal NPs have been reported to exhibit antiviral activity against surrogate models for human norovirus. Broglie et al. [154] produced gold NPs as cores and coated them with copper sulfide nanoshell to inactivate human norovirus-like particles. These NPs at concentrations of 0.083 μM and 1.66 μM inactivated 50% and 100% of the human norovirus virus-like particles, respectively, within a treatment period of 10 min. In this paper, direct binding of the NPs to the virus and damaging of the capsid were mechanisms used by the NPs to inactivate the viral particles [154]. Agnihothram et al. [155] showed that anatase titanium dioxide NPs (20 μg/mL) reduced cell viability of murine norovirus (MNV)-infected RAW 264.7 macrophages by 50% and 75%, at 24 h and 48 h post-infection, respectively. Pfaff et al. [49] reported that exposure to tungsten carbide NPs caused a four-log reduction of MNV within 15 min. Ultimately, their findings also suggested that tungsten carbide NPs may be a promising antiviral agent against norovirus, other non-enveloped, and enveloped viruses [49].
Silver NPs are also considered as promising antiviral agents against human norovirus. Bekele et al. [156] revealed that silver NPs of 10 nm, at concentrations of 50 μg/mL and 100 μg/mL, effectively reduced the titer of feline calicivirus (FCV), a surrogate for human norovirus, beyond the limit of detection. In this paper, the results also showed that the silver NPs of 75 nm and 110 nm presented no significant antiviral effects. Furthermore, treatment with the 10 nm silver NPs reduced FCV capsid protein by 73% compared with the 75 nm and 110 nm silver NPs [156]. Park et al. [157] observed that a novel magnetic hybrid colloid (MHC) conjugated with silver NPs (AgNP-MHCs) caused a two-log reduction in MNV after treatment for 1 h [157]. The study also found that these particles damaged the viral coat proteins and nucleic acids [157]. Castro-Mayorga et al. [158] evaluated the efficacy of silver NP-based films for inactivating the FCV and MNV. Results revealed that exposing the FCV to the silver NP films for 24 h, produced 100% virus inactivation [158]. These evidence-based studies show that metal NPs and their composites can be considered as promising antiviral agents against the human norovirus and agents for disinfectants, food packaging, and contact surface industries.

Poliovirus

Poliovirus, the causative agent of poliomyelitis (polio), consists of a single-stranded positive-sense RNA genome with 7500 nucleotides. There are three serotypes of the wild poliovirus: serotypes 2 and 3, which were eradicated in 2015 and 2019, respectively, while, serotype 1 remains endemic. The clinical features range from mild cases of respiratory illness, gastroenteritis, and malaise to severe forms of paralysis [159, 160]. It can affect different age groups but common in children under 5 years old who have not received the vaccination. There is no cure for polio infection. However, vaccination is recommended for all infants, children, and adults to establish lifelong immunity against the disease [159, 161].

Silver and tungsten carbide NPs have been investigated for antiviral activity against poliovirus. Electrochemical-synthesized 7.1 nm silver NPs of quasi-spherical shape with high purity exhibited anti-poliovirus activity. A concentration of 3.13 ppm reduced the poliovirus infectivity by 50% within 30 min [162]. Huy et al. [162] also stated that the size of the synthesized NPs was smaller than that of poliovirus particles (20–30 nm). Therefore, the NPs could easily interact with the viral particles to inhibit viral binding to the host cells and replication. Pfaff et al. [49] also reported that exposure to tungsten carbide NPs caused a 3.5-log reduction in poliovirus infectivity within 15 min. However, it is unfortunate that research on the use of metal NPs for poliovirus treatment is scanty and warrants further investigation.

Respiratory Syncytial Virus Infection

Respiratory syncytial virus (RSV), a ubiquitous RNA virus [163], is the leading cause of lower respiratory tract infections in infants and adults [164, 165]. Severe RSV infections can exist among premature babies, older adults, infants, adults with the chronic pulmonary or circulatory disease, and immunocompromised individuals [166]. RSV is increasingly recognized as a global health priority because it remains a significant cause of death [165]. It is worth mentioning that except for ribavirin, there is no other treatment and licensed vaccines for RSV [164, 165].

Emerging evidence suggests that silver NPs could potentially be a therapeutic application for RSV infections. In a study by Yang et al. [167], curcumin modified silver NPs exhibited significant antiviral activity against the RSV, at concentrations ranging from 0.008 to 0.12 nM. Based on mechanistic findings, this study further revealed that the curcumin modified silver NPs attached to the viral envelope glycoproteins directly and interfered with the infectivity of RSV [167].

In another cell culture analysis, Morris et al. [168] found that polyvinylpyrrolidone (PVP)-coated silver NPs at a dose of 50 μg/mL decreased RSV replication by 79% and 78% in A549 and HEp-2 cells respectively. Similar antiviral mechanisms of action were noted by Morris et al. [168]. Hence, metal NPs, particularly silver, as antiviral agents for RSV, embrace great potential for future research.

Rift Valley Fever Virus

Rift Valley fever (RVF) virus is a zoonotic mosquito-borne virus, consisting of a three-segment genome of single-stranded RNA [169, 170]. It is associated with periodic epidemics of perinatal deaths and abortions in livestock (i.e., cattle, sheep, and goats), an acute febrile illness, encephalitis, retinitis, blindness, neurological disorders, and hemorrhagic syndrome in humans [171, 172]. RVF is endemic in sub-Saharan African countries, including South Africa [173]. Vaccines that are essential for the containment of RVF outbreaks and antiviral drugs for the effective treatment of RVF are currently unavailable [170]. Thus, research has advanced into investigating the potential application of silver NPs to control RVF infection. Borrego et al. [174] demonstrated that metallic silver NPs at a concentration of 12 μg/mL eradicated viral propagation, resulting in a 98% reduction of viral infectivity. This study also reported that the interaction of silver NPs with the RVF virus affects its infectivity, perhaps by interfering with the virus-cell attachment and viral entry [174]. Further investigations on the application of silver NPs and other metal NPs against RVF infectivity will help combat infection.
Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections

**Rubeola Virus**

Rubeola virus is known as the causative agent of measles. This virus is enveloped with a single-stranded negative-sense RNA and spreads through the respiratory route. Measles is highly contagious with clinical symptoms, including skin rash, fever, cough, coryza, and conjunctivitis [175]. A safe and cost-effective vaccine is available. However, measles is still associated with high mortality rates worldwide, particularly in developing countries with inadequate vaccination and health care facilities. No specific antiviral exists for the treatment of measles. Therefore, HIV-infected children, unvaccinated children, pregnant women, and a vaccinated individual who did not develop immunity are at the highest risk of measles and its complications [176]. A study by Meléndez-Villanueva et al. [177] reported that gold NPs synthesized with garlic extract from *Allium sativa* exhibited antiviral activity against the measles virus at an EC$_{50}$ concentration of 8.829 μg/mL. This study also proposed that the gold NPs displayed virucidal effects by directly blocking viral receptors. Gold NPs may be a promising strategy for the treatment of measles, therefore warrants further investigation.

**Future Perspectives**

Over fifty nanopharmaceuticals have received FDA approval since 1995 that is currently available for clinical use. These include polymeric, liposomal, nanocrystal formulations, micelles, and inorganic (metal) NPs. The first FDA-approved nanof ormulation drug was Doxia (doxorubicin hydrochloride, Janssen) to treat Kaposi’s sarcoma in HIV patients [179–181].

Metal NPs have significant potential to increase the pharmaceutical market growth and improve health benefits for viral diseases. However, the current scientific research, pre-clinical and clinical translation, and regulatory gap for nanomedicines are vast and challenging. Notably, from the outset of metal NP design, it is critical to consider the physicochemical features of different metal NPs, disease pathophysiology, and heterogeneity. Researchers considering these abovementioned factors can assist in tailoring metal NPs with optimal therapeutic benefits. These considerations will also help overcome biological barriers, such as improved targeting and reduced accumulation in non-targeted cells, tissues, and organs. Pre-clinical evaluation for therapeutic efficacy, safety, biodistribution, and pharmacokinetics in appropriate animal models of the disease, relevant to the human condition, is necessary. Before pre-clinical evaluation, extensive in vitro assays for therapeutic efficacy and nanotoxicity screening is essential. After that, pre-clinical toxicology studies in animal models can predict both short-term and long-term toxicity, as circulation half-lives and drug retention times vary with the type of metal ions used for NP synthesis or encapsulation. Monitoring the absorption, distribution, metabolism, and excretion of emerging metal NPs in vivo is also essential to predicting their toxicological safety profile. Additionally, screening of NPs for immunotoxicological and immunomodulation potential is essential since these functional outcomes correlate with tissue uptake and clearance mechanisms [181]. Hence, addressing these issues is critical to safeguard the clinical application of metal NP-based therapeutics for viral infections.

**Conclusion**

Therapeutically, metal NPs, as antiviral agents, are proving to be a promising candidate to tackle current treatment challenges in clinical settings for a broad spectrum of viruses. However, translating the large number of in vitro studies displaying the antiviral activity of metal NPs against different viral infections to pre-clinical and clinical applications is scanty or non-existent. Therefore, scientific evidence gained through research addressing these priority areas can help tailor and synthesize clinically translatable nanosized metal particles to treat viral diseases.

**Funding** The authors would like to thank the College of Health Sciences, University of KwaZulu-Natal and National Health Laboratory Services for financial support.

**Compliance with Ethical Standards**

**Conflict of Interest** The authors declare that they have no conflict of interest.

**References**

1. Aderibigbe BA (2017) Metal-based nanoparticles for the treatment of infectious diseases. Molecules 22(8):1370
2. Joob B, Wiwanitkit V (2017) Nanotechnology for health: A new useful technology in medicine. Medi J Dr DY Patil Univ 10(5):401
3. Prasad M, Lambe UP, Brar B, Shah I, J M, Ranjan K, Rao R, Kumar S, Mahant S, Khurana SK, Iqbal HMN, Dhma K, Misri J, Prasad G (2018) Nanotherapeutics: an insight into healthcare and multi-dimensional applications in medical sector of the modern world. Biomed Pharmacother 97:1521–1537
4. Nikalje AP (2015) Nanotechnology and its applications in medicine. Med Chem 5(2):081–089
5. Anselmo AC, Mitragotri S (2016) Nanoparticles in the clinic. Bioeng Translat Med 1(1):10–29
6. Galdiero M (2011) Silver nanoparticles as potential antiviral agents. Molecules 16(10):8894–8918
7. Khandel P, Yadaw RK, Soni DK, Kanwar L, Shahi SK (2018) Biogenesis of metal nanoparticles and their pharmacological applications: present status and application prospects. J Nanostruct Chemistry 8(3):217–254
51. Nikaeen G, Abbaszadeh S, Yousefinejad S (2020) Application of nanomaterials in treatment, anti-infection and detection of coronaviruses. Nanomedicine 15:1501–1512
52. Sekimukai H, Iwata-Yoshikawa N, Fukushima S, Tani H, Katoaka M, Suzuki T, Hasegawa H, Niikura K, Arai K, Nagata N (2020) Gold nanoparticle-adjuvant S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit epoxiphilic infiltration in lungs. Microbiol Immunol 64(1):33–51
53. Nasrollahzadeh M, Sajjadi M, Soufi GJ, Iravani S, Varma RS (2020) Nanomaterials and nanotechnology-associated innovations against viral infections with a focus on coronaviruses. Nanomaterials 10(6):1072
54. Sportelli MC, Izzo M, Kukushkina EA, Hossain SI, Sicca RA, Ditaranto N, Cioffi N (2020) Can nanotechnology and materials science help the fight against SARS-CoV-2? Nanomaterials 10(4):802
55. Huang X, Li M, Xu Y, Zhang J, Meng X, An X, Sun L, Guo L, Shan X, Ge J, Chen J, Luo Y, Wu H, Zhang Y, Jiang Q, Ning X (2019) Novel gold nanorod-based H1N1 peptide inhibitor for middle east respiratory syndrome coronavirus. ACS Appl Mater Interfaces 11(22):19799–19807
56. Du T et al (2018) Glutathione-capped Ag2S nanoclusters inhibit coronavirus proliferation through blockage of viral RNA synthesis and budding. ACS Appl Mater Interfaces 10(5):4369–4378
57. Chen Y-N, Hsueh Y-H, Hsieh C-T, Tzou D-Y, Chang P-L (2016) Antiviral activity of graphene–silver nanocomposites against non-enveloped and enveloped viruses. Int J Environ Res Public Health 13(4):40
58. Balagna C, Perero S, Percivalle E, Nepita EV, Ferraris M (2020) Virucidal effect against Coronavirus SARS-CoV-2 of a silver nanocluster/silica composite sputtered coating. Open Ceram 1:10006
59. Ventarola D, Bordone L, Silverberg N (2015) Update on hand-foot-and-mouth disease. Clin Dermatol 33(3):340–346
60. Wang M, Li J, Yao MX, Zhang YW, Hu T, Carr MJ, Duchêne S, Zhang XC, Zhang ZJ, Zhou H, Tong YG, Ding SJ, Wang XJ, Shi WF (2019) Genome analysis of coxsackievirus A4 isolates from Shandong, China. Front Microbiol 10:1001
61. Kimmis BD, Christopher D, Stephen T (2018) Hand-foot-and-mouth disease caused by coxsackievirus A6 on the rise. Cutis 102:353–356
62. Salem BAN et al (2012) Plant-derived nanoparticles enhance antiviral activity against coxsackievirus B3 by acting on virus particles and vero cells. Digest J Nanomater Biostruct 7(2):737–744
63. Haggag EG et al (2019) Antiviral potential of green synthesized silver nanoparticles of Lampranthus coccineus and Malopehita lutea. Int J Nanomedicine 14:6217–6229
64. Zhong J, Xia Y, Hua L, Liu X, Xiao M, Xu T, Zhu B, Cao H (2019) Functionalized selenium nanoparticles enhance the anti-EV71 activity of oselemivir in human astrocytoma cell model. Artif Cells Nanomed Biotechnol 47(1):3485–3491
65. Li Y, Xu T, Lin Z, Wang C, Xia Y, Guo M, Zhao M, Chen Y, Zhu B (2019) Inhibition of enterovirus A71 by selenium nanoparticles interacts with JNK signaling pathways. ACS Omega 4(4):6720–6725
66. Ceballos-OLvera I, Chávez-Salinas S, Medina F, Ludert JE, del Angel RM (2010) JNK phosphorylation, induced during dengue virus infection, is important for viral infection and requires the presence of cholesterol. Virology 396(1):30–36
67. Paiva CN, Bozza MT (2014) Are reactive oxygen species always detrimental to pathogens? Antioxid Redox Signal 20(6):1000–1037
68. Shragai T et al (2017) Zika and chikungunya: mosquito-borne viruses in a changing world: global change and vectors of chikungunya and Zika. Ann NY Acad Sci 1:1–17
69. Weaver S (2006) Evolutionary influences in arboviral disease, in Quasispecies: concept and implications for virology. pp 285–314
70. Silva JV Jr et al (2018) A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control. Acta Trop 188:213–224
71. Gerardin P et al (2008) Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Reunion. PLoS Med 5(3):414–423
72. Silva LA, Demody T (2017) Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest 127(3):737–749
73. Nathrajan MS, Rojas A, Waggoner JJ (2019) Beyond fever and pain: diagnostic methods for chikungunya virus. J Clin Microbiol 57(6):e00350–e00319
74. Karthi S, Shivakumar MS (2016) Vector control in chikungunya and other arboviruses. Curr Topics Chikungunya 24:123–130
75. Kaushik S et al (2019) Anti-chikungunya activity of green synthesized silver nanoparticles using carica papaya leaves in animal cell culture model. Asian J Pharm Clin Res 12(6):170–174
76. Sharma V, Kaushik S, Pandit P, Dhull D, Yadav JP, Kaushik S (2019) Green synthesis of silver nanoparticles from medicinal plants and evaluation of their antiviral potential against chikungunya virus. Appl Microbiol Biotechnol 103(2):881–891
77. Kumar R, Sahoo G, Pandey K, Nayak MK, Topno R, Rabidas V, Das P (2018) Virostatic potential of zinc oxide (ZnO) nanoparticles on capsid protein of cytoplastic side of chikungunya virus. Int J Infect Dis 73:368
78. Selvan SM et al (2018) Green synthesis of copper oxide nanoparticles and mosquito larvicidal activity against dengue, Zika and chikungunya causing vector Aedes aegypti. IET Nanobiotechnol 12(8):1042–1046
79. Morejón B et al (2018) Larvicidal activity of silver nanoparticles synthesized using extracts of Ambrosia arborescens (Asteraceae) to control Aedes aegypti (Diptera: Culicidae). J Nanotechnol 2018:1–9
80. Balaji, S.M. and K. Manjula, Biosynthesis of silver nanocomposites using agro waste and its larvicidal properties, 2018.
81. Alshehri MA et al (2020) Phytochemical analysis of Rhazya stricta extract and its use in fabrication of silver nanoparticles effective against mosquito vectors and microbial pathogens. Sci Total Environ 700:134443
82. Sudamani D, Jaya Durkga S, Nagarani N (2018) Effect of silver nanoparticles synthesized from Daemia extensa against the dengue and chikungunya vector, Aedes aegypti. Int J Res Appl Sci Eng Technol 6(VII):529–535
83. Pilaquinga F et al (2019) Green synthesis of silver nanoparticles using Solanum mammosum L. (Solanaceae) fruit extract and their larvicidal activity against Aedes aegypti L. (Diptera: Culicidae). PLoS One 14(10):1–13
84. Benelli G (2016) Green synthesized nanoparticles in the fight against mosquito-borne diseases and cancer—a brief review. Enzym Micrib Technol 95:58–68
85. Kumar R et al (2020) Dengue fever: a review article. Int J Curr Microbiol App Sci 9(1):1502–1510
86. Khetarpal N, Khanna I (2016) Dengue fever: causes, complications, and vaccine strategies. J Immunol Res 2016:1–13
87. Guzman MG et al (2016) Biosynthesis of copper nanoparticles using Arctocarpus heterophyllus against dengue vector Aedes aegypti. Int J Life Sci Scienti Res eISSN 2455(1716):1716
89. Abinaya M, Vaseeharan B, Rekha R, Shanthini S, Govindanraj M, Albari NS, Kadaikunnan S, Khaled JM, al-Anber MN (2019) Microbial exopolymer-capped selenium nanowires–towards new antibacterial, antifilmogen and arbovirus vector larvicides? J Photocem Photobiol B Biol 192:55–67
90. Murugan K, Benelli G, Panneerselvam C, Subramaniam J, Jeyalahitha T, Dinesh D, Nicoletti M, Hwang JS, Suresh U, Madhiyazagham P (2015) Cymbopogon citratus-synthesized gold nanoparticles boost the predation efficiency of copepod Mesocyclops aspericornis against malaria and dengue mosquitoes. Exp Parasitol 153:129–138
91. Sundararajan B, Kumari BR (2017) Novel synthesis of gold nanoparticles using Artemisia vulgaris L. leaf extract and their efficacy of larvicidal activity against dengue fever vector Aedes aegypti L. J Trace Elem Med Biol 43:187–196
92. Benelli G (2018) Gold nanoparticles–against parasites and insect vectors. Acta Trop 178:73–80
93. Nalini M, Lena M, Sumathi P, Sundaravdevian C (2017) Effect of phyto-synthesized silver nanoparticles on developmental stages of malaria vector, Anopheles stephensi and dengue vector, Aedes aegypti. Egypt J Basic Appl Sci 4(3):212–218
94. Santhosh S, Yuvarajan R, Natuarjan D (2015) Annona muricata leaf extract-mediated silver nanoparticles synthesis and its larvicidal potential against dengue, malaria and filariasis vector. Parasitol Res 114(8):3087–3096
95. Banu AN, Balasubramanian C, Moothir PV (2014) Biosynthesis of silver nanoparticles using Bacillus thuringiensis against dengue vector, Aedes aegypti (Diptera: Culicidae). Int J Innovat Technol Explor Eng 8:753–757
96. Ghrarn HA, al-Ghamdi KM, Mahyoub JA, Ibrahim EH (2018) Chrysanthemum extract and extract prepared silver nanoparticles as biocides to control Aedes aegypti (L.), the vector of dengue fever. J Asia Pac Entomol 21(1):205–210
97. Osanloo M et al (2019) Larvicidal activity of chemically synthesized silver nanoparticles against Anopheles stephensi. J Pharmaceut Negat Results 10(1):69
98. Jin U, Rajakumaran S, Senthil-Nathan S, Geetha N, Venkatachalam P (2018) Potential larvicidal activity of silver nanohybrids synthesized using leaf extracts of Cleistanthus collinus (Roxb.) Benth. ex Hook. f. and Styrchnos nux-vomica L. nux-vomica against dengue, chikungunya and Zika viruses. Physiol Mol Plant Pathol 101:163–171
99. Deepak P, Sowmini R, Ramkumar R, Balaasubramani G, Aiswarya D, Perumal P (2017) Structural characterization and evaluation of mosquito-larvicidal property of silver nanoparticles synthesized from the seaweed, Turbinaoria ornata (Turner) J. Agardh 1848. Artif Cells Nanomed Biotechnol 45(5):990–998
100. Elumalai D, Hemavathi M, Deepaa CV, Kaleena PK (2017) Evaluation of phytothesynthesized silver nanoparticles from leaf extracts of Leucas aspera and Hypis suaveolens and their larvicidal activity against malaria, dengue and filariasis vectors. Parasite Epidemiol Contr 20(4):15–26
101. Ravi R et al (2019) Larvicidal effects of nano-synthesized silver nanoparticles from Azolla pinnata extract against Aedes aegypti (Diptera: Culicidae). Int J Innovat Technol Explor Eng 8:753–757
102. Parthiban E, Manivannan N, Ramanibai R, Mathivanan N (2019) Green synthesis of silver-nanoparticles from Annona reticulata leaves aqueous extract and its mosquito larvicidal and antimalarial activity on human pathogens. Biotechnol Rep 21: e00297
103. Soni N, Prakash S (2014) Green nanoparticles for mosquito control. Sci World J 2014:1–6
104. Vignesh M, Moothri PV (2017) An overview of naturally synthesized metallic nanoparticles. J Appl Pharmaceut Sci 7(06):229–237
105. Paul AM, Shi Y, Acharya D, Douglas JR, Cooley A, Anderson JF, Huang F, Bai F (2014) Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro. J Gen Virol 95(Pt 8):1712–1722
106. Quach QH, Ang SK, Chu JHI, Kah JCY (2018) Size-dependent neutralizing activity of gold nanoparticle-based subunit vaccine against dengue virus. Acta Biomater 78:224–235
107. Murugan K, Aruna P, Panneerselvam C, Madhiyazagham P, Paulpandi M, Subramaniam J, Rajaganesh R, Wei H, Alsalhi MS, Devanesan S, Nicoletti M, Syuhli B, Canale A, Benelli G (2016) Fighting arboviral diseases: low toxicity on mammalian cells, dengue growth inhibition (in vitro), and mosquitoicidal activity of Centrocercus clavulatum-synthesized silver nanoparticles. Parasitol Res 115(2):651–662
108. Murugan K, Dinesh D, Paulpandi M, Alithbyani ADM, Subramaniam J, Madhiyazagham P, Wang L, Suresh U, Kumar PM, Mohan J, Rajaganesh R, Wei H, Kalimuthu K, Parajulee MN, Mehlihom H, Benelli G (2015) Nanoparticles in the fight against mosquito-borne diseases: bioactivity of Bruguiera cylindrica-synthesized nanoparticles against dengue virus DEN-2 (in vitro) and its mosquito vector Aedes aegypti (Diptera: Culicidae). Parasitol Res 114(12):4349–4361
109. Sujitha V, Murugan K, Paulpandi M, Panneerselvam C, Suresh U, Roni M, Nicoletti M, Higuchi A, Madhiyazagham P, Subramaniam J, Dinesh D, Vadivalagan C, Chandramohan B, Alaraj AA, Munusamy MA, Barnard DR, Benelli G (2015) Green-synthesized silver nanoparticles as a novel control tool against dengue virus (DEN-2) and its primary vector Aedes aegypti. Parasitol Res 114(9):3315–3325
110. Álvarez DM, Castillo E, Duarte LF, Arriagada J, Corrales N, Farias MA, Henríquez A, Agurto-Muñoz C, González PA (2020) Current antivirals and novel botanical molecules interfering with herpes simplex virus infection. Front Microbiol 11:139
111. Ayoub HH, Chemaïtelli H, Abu-Raddad LJ (2019) Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions. BMC Med 17(1):57
112. Crimi S, Fiorillo L, Bianchi A, D’Amico C, Amoroso G, Gorassini F, Mastroieni R, Marino S, Scoglio C, Catalano F, Campagna P, Bocchieri S, de Stefano R, Fiorillo MT, Cicciù M (2019) Herpes virus, oral clinical signs and QoL: systematic review of recent data. Viruses 11(5):463
113. Tavakoli A, Hashemzadeh MS (2020) Inhibition of herpes simplex virus type 1 by copper oxide nanoparticles. J Virol Methods 275:136088
114. Hang X, Peng H, Song H, Qi Z, Miao X, Xu W (2015) Antiviral activity of cuprous oxide nanoparticles against hepatitis C virus in vitro. J Virol Methods 222:150–156
115. Farouk F, Shebl RI (2018) Comparing surface chemical modifications of zinc oxide nanoparticles for modulating their antiviral activity against herpes simplex virus type-1. Int J Nanopart Nanotechnol 4(021):1–14
116. Tavakoli A, Ataei-Pirkooh A, MM Sadeghi G, Bokharaei-Salim F, Sahrapour P, Kiani SJ, Moghoofeei M, Farahmand M, Javanmand D, Monavari SH (2018) Polyethylene glycol-coated zinc oxide nanoparticle: an efficient nanoweapon to fight against herpes simplex virus type 1. Nanomedicine 13(21):2675–2690
117. Dhanasezhian A et al. (2019) Anti-herpes simplex virus (HSV-1 and HSV-2) activity of biogenic gold and silver nanoparticles using seaweed Sargassum wightii. Indian J Mar Sci 45(08):1252–1257
118. Cagno V, Andreozzi P, D’Alicamassino M, Jacob Silva P, Mueller M, Galloux L, Le Goffic R, Jones ST, Vallino M, Hodek J, Weber J, Sen S, Janček ER, Bekdemir A, Sanavio B, Martinelli C, Donaliso M, Rameix Welti MA, Eleouet JF, Han Y, Kaiser L, Vukovic L, Tapparel C, Král P, Krol S, Lembo D, Stellacci F
Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections

(2018) Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nat Mater 17(2):195–203

119. Halder A, Das S, Ojha D, Chattopadhyay D, Mukherjee A (2018) Highly monodispersed gold nanoparticles synthesis and inhibition of herpes simplex virus infections. Mater Sci Eng C 89:413–421

120. Orłowski P, Kowalczyk A, Tomaszewska E, Ranaszek-Soliwoda K, Węgrzyn A, Grzesiak J, Celichowski G, Grobelny J, Eriksson K, Krzywowska M (2018) Antiviral activity of tannic acid modified silver nanoparticles: potential to activate immune response in herpes genitalis. Viruses 10(10):524

121. Hu R et al (2014) Inhibition effect of silver nanoparticles on herpes simplex virus 2. Genet Mol Res 13(3):7022–7028

122. Gaikwad S et al (2013) Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3. Int J Nanomedicine 8:4303

123. Akbarzadeh A, Kafshdooz L, Razban Z, Dastranj Tbrizi A, Halder A, Das S, Ojha D, Chattopadhyay D, Mukherjee A (2018) An overview application of silver nanoparticles in inhibition of herpes simplex virus. Artif Cells Nanomed Biotechnol 46(2):263–267

124. Etemadzade M, Ghamarypour A, Zabihollahi R, Shabbak G, Pandey A, Galvani AP (2019) The global burden of HIV and AIDS: where are we now? Med Res Rev 39(3):860–911

125. Sadowski I, Hashemi FB (2019) Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs. Cell Mol Life Sci 76:3583–3600

126. Pandey A, Galvani AP (2019) The global burden of HIV and prospects for control. Lancet HIV 6(12):e809–e811

127. Eisinger RW, Folkers GK, Fauci AS (2019) Ending the human immunodeficiency virus pandemic: optimizing the prevention and treatment toolkits. Clin Infect Dis 69(12):2212–2217

128. Vijayakumar S, Ganesan S (2012) Gold nanoparticles as an HIV entry inhibitor. Curr HIV Res 10(8):643–646

129. Marradi M, di Gianvincenzo P, Enríquez-Navas PM, Martínez-Ávila OM, Chiado F, Yuste E, Angulo J, Penadés S (2011) Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12. J Mol Biol 410(5):798–810

130. Soto ER, O’Connell O, Dikengii F, Peters PJ, Clapham PR, Ostroff GR (2016) Targeted delivery of glucan particle encapsulated gallium nanoparticles inhibits HIV growth in human macrophages. J Drug Deliv 2016:1–8

131. Choi S-r, Britigan BE, Narayanasamy P (2017) Ga (III) nanoparticles inhibit growth of both Mycobacterium tuberculosis and HIV and release of interleukin-6 (IL-6) and IL-8 in coinfected macrophages. Antimicrob Agents Chemother 61(4):e02505–e02516

132. Ardestani MS, Fordoei AS, Abdoli A, Ahangari Coehan R, Bahramali G, Sadat SM, Siadat SD, Moloudian H, Nassiri Koopaei N, Bolhasani A, Rahimi P, Hekmat S, Davari M, Aghasadeghi MR (2015) Nanosilver based anionic linear globular dendrimer with a special significant antituberculosis activity. J Mater Sci Med 26(5):179–187

133. Hewlings SJ, Kalman DS (2017) Curcumin: a review of its antiviral activities. J Photochem Photobiol B Biol 188:6–11

134. Sharma RK, Cwiklinski K, Aalinekkel R, Reynolds JL, Sykes DE, Quaye E, Oh J, Mahajan SD, Schwartz SA (2017) Immunomodulatory activities of curcumin-stabilized silver nanoparticles: efficacy as an antituberculosis therapeutic. Immunol Invest 46(8):833–846

135. Sharma A, Yadav A, Gupta N, Sharma S, Kakkar R, Cwiklinski K, Quaye E, Mahajan SD, Schwartz SA, Kumar Sharma R (2019) Multifunctional mesoporous curcumin encapsulated iron-phenanthroline nanocluster: a new Anti-HIV agent. Colloids Surf B: Biointerfaces 180:289–297

136. Do A, Reau NS (2020) Chronic viral hepatitis: current management and future directions. Hepatol Commun 4(3):329–341

137. Thomas DL (2019) Global elimination of chronic hepatitis. N Engl J Med 380(21):2041–2050

138. Lu L, Sun RW, Chen R, Hui CK, Ho CM, Luk JM, Lau GK, Che CM (2008) Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther 13(2):253–262

139. Dharmapalan D (2020) Influenza. Indian J Pediatr 87:828–832

140. Paules C, Subbarao K (2017) Influenza. Lancet 390(10095):697–708

141. Taubenberger JK, Morens DM (2010) Influenza: the once and future pandemic. Public Health Rep 125(3_suppl):15–26

142. Meseko C, Kumar B, Saincas M (2018) In: Saxena SK (ed) Preventing zoonotic influenza. Influenza-Therapeutics and Challenges. IntechOpen, London, pp 33–55

143. Kumar R, Nayak M, Sahoo GC, Pandey K, Sarkar MC, Ansari Y, Das VNR, Topno RK, Bhawna, Madhukar M, Das P (2019) Iron oxide nanoparticles based antiviral activity of H1N1 influenza A virus. J Infect Chemother 25(5):325–329

144. Lin L, Li Y, Gong G, Xia Y, Wang C, Chen Y, Hua L, Zhong J, Tang Y, Liu X, Zhu B (2018) Restriction of H1N1 influenza virus infection by selenium nanoparticles loaded with ribavirin via resisting caspase-3 apoptotic pathway. Int J Nanomedicine 13: 5787–5797

145. Li Y, Lin Z, Zhao M, Xu T, Wang C, Hua L, Wang H, Xia H, Zhu B (2016) Silver nanoparticle based codelivery of oseltamivir to inhibit the activity of the H1N1 influenza virus through ROS-mediated signaling pathways. ACS Appl Mater Interfaces 8(37): 24385–24393

146. Alghfar ZK, Fergi DG, Ebrahim B (2019) Enhanced inhibition of influenza virus infection by peptide-noble-metal nanoparticle conjugates. Beilstein J Nanotechnol 10(1):1038–1047

147. Fatima M, Zaidi NUSS, Amraiz D, Afzal F (2016) In vitro antiviral activity of Cinnamomum cassia and its nanoparticles against H7N3 influenza a virus. J Microbiol Biotechnol 26(1):151–159

148. Xiang D, Chen Q, Pang L, Zheng CL (2011) Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro. J Virol Methods 178(1–2):137–142

149. Xiang D et al (2013) Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo. Int J Nanomedicine 8:4103

150. Steekant H et al (2018) Ultra-sorption-assisted silver nanoparticles using Panax ginseng root extract and their anti-cancer and antiviral activities. J Photochem Photobiol B Biol 188:6–11

151. Parra GI (2019) Emergence of norovirus strains: a tale of two genes. Virus Evolut 5(2):vez048

152. Mans J (2019) Norovirus infections and disease in lower-middle- and low-income countries, 1997–2018. Viruses 11(4):341

153. Netzler NE, Enosi Tuipulotu D, White PA (2019) Norovirus anti-virals: where are we now? Med Res Rev 39(3):860–886

154. Broglie JJ et al (2015) Antiviral activity of gold/copper sulfide core/shell nanoparticles against human norovirus-like particles. PLoS One 10(10):1–14

155. Agnihotram S, Mullis L, Townsend TA, Watanabe F, Mustafa T, Biris A, Manjanatha MG, Azvedo MP, United States Food and Drug Administration, National Center for Toxicological Research (2016) Titanium dioxide nanoparticles evoke proinflammatory response during Murine norovirus infection despite having minimal effects on virus replication. Int J Nanotechnol Med Eng 1(3):63–73

156. Bekele AZ, Gokulan K, Williams KM, Khare S (2016) Dose and size-dependent antiviral effects of silver nanoparticles on feline calcivirus, a human norovirus surrogate. Foodborne Pathog Dis 13(5):239–244

Springer
157. Park S, Park HH, Kim SY, Kim SJ, Woo K, Ko GP (2014) Antiviral properties of silver nanoparticles on a magnetic hybrid colloid. Appl Environ Microbiol 80(8):2343–2350

158. Castro-Mayorga JL, Randazzo W, Fabra MJ, Lagaron JM, Aznar R, Sánchez G (2017) Antiviral properties of silver nanoparticles against norovirus surrogates and their efficacy in coated polyhydroxyalkanoates systems. LWT-Food Sci Technol 79:503–510

159. Maman KZ et al (2020) Moving from oral poliovirus vaccine to inactivated poliovirus vaccine: the rationale and challenges. Bangladesh J Med 31(1):22–28

160. Ghafoor S, Sheikh N (2016) Eradication and current status of poliomyelitis in Pakistan: ground realities. J Immunol Res 2016:1–6

161. Ali SA et al (2015) Polio—an endemic disease in Pakistan: literature review. i-manager’s J Nurs 5(1):29

162. Huy TQ, Hien Thanh NT, Thuy NT, Hung PN, le AT, Hong Hanh NT (2017) Cytotoxicity and antiviral activity of electrochemical–synthesized silver nanoparticles against poliovirus. J Virol Methods 241:52–57

163. Lanari M, Vandini S, Capretti MG, Lazzarotto T, Faldella G (2014) Respiratory syncytial virus infections in infants affected by primary immunodeficiency. J Immunol Res 2014:1–6

164. Meng J et al (2014) An overview of respiratory syncytial virus. PLoS Pathog 10(4):1–4

165. Nam HH, Isom MG (2019) Respiratory syncytial virus infection in adults. bmj 366:l5021

166. Griffiths C, Drews SJ, Marchant DJ (2017) Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev 30(1):277–319

167. Yang XX, Li CM, Huang CZ (2016) Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection. Nanoscale 8(5):3040–3048

168. Morris D, Ansar M, Seshock J, Ivanciuc T, Qu Y, Casola A, Garofalo R (2019) Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection. Viruses 11(8):732

169. Lumley S, Horton DL, Hernandez-Triana LLM, Johnson N, Fooks AR, Hewson R (2017) Rift valley fever virus: strategies for maintenance, survival and vertical transmission in mosquitoes. J Gen Virol 98(5):875–887

170. Javelle E, Lesueur A, Pommier de Santi V, de Laval F, Lefebvre T, Holweck G, Durand GA, Lepare-Golliart I, Texier G, Simon F (2020) The challenging management of Rift Valley Fever in humans: literature review of the clinical disease and algorithm proposal. Ann Clin Microbiol Antimicrob 19(1):4

171. Ikegami T, Makino S (2011) The pathogenesis of Rift Valley fever. Viruses 3(5):493–519

172. Ngenga MK, Bett B (2019) Rift Valley fever virus—how and where virus is maintained during inter-epidemic periods. Curr Clin Microbiol Rep 6(1):18–24

173. Jansen van Vuren P et al (2018) Human cases of Rift Valley fever in South Africa, 2018. Vector-Borne Zoonotic Dis 18(12):713–715

174. Borrego B, Lorenzo G, Mota-Morales JD, Almanza-Reyes H, Mateos F, López-Gil E, de la Losa N, Burmistrov VA, Pestryakov AN, Brun A, Bogdanchikova N (2016) Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo. Nanomedicine 12(5):1185–1192

175. Griffin DE (2014) Measles virus and the nervous system. In: Handbook of clinical neurology. 123:577–590

176. Naim HY (2015) Measles virus: a pathogen, vaccine, and a vector. Human Vacc Immunotherapeut 11(1):21–26

177. Meléndez-Villanueva MA, Morán-Santibañez K, Martínez-Sanmiguel JJ, Rangel-López R, Garza-Navarro MA, Rodríguez-Padilla C, Zarate-Triviño DG, Trejo-Ávila LM (2019) Virucidal activity of gold nanoparticles synthesized by green chemistry using garlic extract. Viruses 11(12):1111

178. Kumar SD, Singaravelu G, Ajithkumar S, Murugan K, Nicoletti M, Benelli G (2017) Mangrove-mediated green synthesis of silver nanoparticles with high HIV-1 reverse transcriptase inhibitory potential. J Clust Sci 28(1):359–367

179. Ventola CL (2017) Progress in nanomedicine: approved and investigational nanodrugs. Pharm Therapeut 42(12):742–755

180. Cojocaru F-D, Botezat D, Gardikiotis I, Uritu CM, Dodi G, Trandafir L, Rezus C, Rezus E, Tamba BI, Mihai CT (2020) Nanomaterials designed for antiviral drug delivery transport across biological barriers. Pharmaceutics 12(2):171

181. Hua S, de Matos MBC, Metselaar JM, Storm G (2018) Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol 9:790

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.